About Kai Fu
- Professor of Oncology
- Vice Chair of Hematopathology
- Department of Pathology & Laboratory Medicine
Education and Training:
- 1997 - PhD - Biochemistry and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS
- 1990 - MD - Medicine, Tianjin Medical University, Tianjin, China
- 1998-2002 - Anatomic and Clinical Pathology, University of Alabama at Birmingham, Birmingham, AL
- 2002-2004 - Hematopathology fellowship, University of Nebraska Medical Center, Omaha, NE
- 2001-2002 - Surgical Pathology fellowship, University of Alabama at Birmingham, Birmingham, AL
- 2005 - American Board of Pathology: Hematopathology (hematology)
- 2002 - American Board of Pathology: Anatomic and Clinical Pathology
- 09/2020–Present - Professor and Chief, Division of Hematopathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York
- 07/2014–08/2020 - Professor, Department of Pathology & Microbiology, University of Nebraska Medical Center (UNMC)
- 07/2014–08/2020 - Co-Director, James O. Armitage Center for Hematological Malignancies Research, Fred & Pamela Buffett Cancer Center, UNMC
- 07/2009–06/2014 - Associate Professor, Department of Pathology & Microbiology, UNMC
- 07/2004–06/2009 - Assistant Professor, Department of Pathology & Microbiology, UNMC
- 07/1990 – 07/1992 - Junior Investigator, Institute of Endocrinology, Tianjin Medical University, China
Honors & Awards:
- 2009-2012 - Millennium Pharmaceuticals, Inc. / Lymphoma Research Foundation Clinical Investigator Career Development Award
- 2009 - K12 Clinical and Translational Research Scholar, UNMC
- 2008 - Distinguished Young Scientist of the Year, Lymphoma Foundation of America
- 2006 - CureSearch Research Fellowship Award, Children’s Oncology Group
- 2001 - Paul E. Strandjord Young Investigator Award: Academy of Clinical Laboratory Physicians and Scientists
- 1997 - Young Scientist Award: the 17th International Congress of Biochemistry & Molecular Biology
- 1997 - Kansas Health Foundation Post-doctoral Fellow: University of Kansas
As a physician-scientist, my research interests focus on understanding the molecular mechanisms in lymphomagenesis and the identification of novel therapeutic strategies for malignant lymphomas.
1. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, DeJong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Braziel RM, Müller- Hermelink HK, Campo E, Gascoyne RD, Staudt LM, and Chan WC. Cyclin D1-negative Mantle Cell Lymphoma: A Clinicopathological Study Based on Gene Expression Profiling. Blood 2005: 106 (13):4315-21.
2. Bi CF, Zhang X, Lu T, Zhang XY, Wang XH, Meng B., Zhang HL, Wang P., Vose JM, Chan WC., McKeithan TW, and Fu K. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mTOR kinase inhibitors in aggressive B-cell lymphomas. Haematologica 2017 Apr; 102(4): 755-764.
3. Jiang C, Bi C, Jiang X, Tian T, Huang X, Wang C, Fernandez MR, Iqbal J, Chan WC, McKeithan TW, Lewis RE, and Fu K. The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway. Br J Haematol. 2019 May;185 (3):616-620. PMID: 30198569
4. Ren Y, Bi CF, Zhao XH, Lwin T, Wang C, Yuan J, Silva AS., Shah BD., Fang B., Li T., Koomen JM., Jiang HJ., Chavez JC., Pham L, Sudalagunta PR., Wan LX., Wang XF., Dalton WS., Moscinski LC., Shain KH., Vose JM., Cleveland JL., Sotomayor EM., Fu K.*, Tao JG*. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest 2018 Dec 3; 128(12): 5517-5530. (*: Co-corresponding authors)
5. Zhang X, Bi C, Lu T, Zhang W, Yue T, Wang C, Tian T, Zhang X, Huang Y, Lunning M, Hao X, Brown LE, Devine WG, Vose J, Porco JA Jr, Fu K. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas. Leukemia. 2020 Jan; 34(1):138-150.